Cargando…

Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors

BACKGROUND/OBJECTIVES: Lowering low-density lipoprotein cholesterol (LDLc) in type 2 diabetes mellitus is of paramount importance in preventing cardiovascular disease. However, treatment targets for LDLc are often not reached. We studied the prevalence of LDLc target achievement in a real-life popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Gant, Christina M., Binnenmars, S. Heleen, Harmelink, Manon, Soedamah-Muthu, Sabita S., Bakker, Stephan J. L., Navis, Gerjan, Laverman, Gozewijn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917033/
https://www.ncbi.nlm.nih.gov/pubmed/29695715
http://dx.doi.org/10.1038/s41387-018-0028-y
_version_ 1783317117319249920
author Gant, Christina M.
Binnenmars, S. Heleen
Harmelink, Manon
Soedamah-Muthu, Sabita S.
Bakker, Stephan J. L.
Navis, Gerjan
Laverman, Gozewijn D.
author_facet Gant, Christina M.
Binnenmars, S. Heleen
Harmelink, Manon
Soedamah-Muthu, Sabita S.
Bakker, Stephan J. L.
Navis, Gerjan
Laverman, Gozewijn D.
author_sort Gant, Christina M.
collection PubMed
description BACKGROUND/OBJECTIVES: Lowering low-density lipoprotein cholesterol (LDLc) in type 2 diabetes mellitus is of paramount importance in preventing cardiovascular disease. However, treatment targets for LDLc are often not reached. We studied the prevalence of LDLc target achievement in a real-life population of type 2 diabetes mellitus patients in secondary care, and investigated whether in those not on target, there is room for intensifying pharmacological and lifestyle management according to current treatment guidelines. SUBJECTS/METHODS: We performed a cross-sectional analysis in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1; n = 450, age 63 ± 9 years, 58% men, diabetes duration 11 (7–18) years). At baseline, we determined plasma LDLc concentration, pharmacological treatment (i.e., statin use), and lifestyle (physical activity and dietary intake). Patients were divided according to LDLc < 1.8, LDLc 1.8–2.5, and LDLc > 2.5 mmol/l. Dietary intake was collected from a validated Food Frequency Questionnaire (177 items) and we determined guideline adherence for different food groups. Physical activity was assessed with the Short Questionnaire to ASsess Health enhancing behavior. RESULTS: LDLc data were available in 428 type 2 diabetes mellitus patients. LDLc ≤ 2.5 mmol/l was achieved in 317 patients (76%). In total, 76% of patients used statins, in those with LDLc > 2.5 mmol/l, this was 44%. Adherence to lifestyle guidelines was not different between the LDLc groups and was as follows: body mass index 6%, physical activity 59%, vegetables 7%, fruit 28%, legumes 59%, nuts 14%, dairy 19%, fish 36%, tea 8%, fats 66%, red meat 12%, processed meat 2%, alcohol 71%, sweetened beverages 34%, and sodium 12%. CONCLUSIONS: In type 2 diabetes mellitus patients in secondary health care, the target LDLc is achieved by three quarters of patients. Increasing statin treatment could be a first step to improve LDLc. In addition, there are ample opportunities for lifestyle management through increasing adherence to lifestyle guidelines.
format Online
Article
Text
id pubmed-5917033
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59170332018-04-27 Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors Gant, Christina M. Binnenmars, S. Heleen Harmelink, Manon Soedamah-Muthu, Sabita S. Bakker, Stephan J. L. Navis, Gerjan Laverman, Gozewijn D. Nutr Diabetes Article BACKGROUND/OBJECTIVES: Lowering low-density lipoprotein cholesterol (LDLc) in type 2 diabetes mellitus is of paramount importance in preventing cardiovascular disease. However, treatment targets for LDLc are often not reached. We studied the prevalence of LDLc target achievement in a real-life population of type 2 diabetes mellitus patients in secondary care, and investigated whether in those not on target, there is room for intensifying pharmacological and lifestyle management according to current treatment guidelines. SUBJECTS/METHODS: We performed a cross-sectional analysis in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1; n = 450, age 63 ± 9 years, 58% men, diabetes duration 11 (7–18) years). At baseline, we determined plasma LDLc concentration, pharmacological treatment (i.e., statin use), and lifestyle (physical activity and dietary intake). Patients were divided according to LDLc < 1.8, LDLc 1.8–2.5, and LDLc > 2.5 mmol/l. Dietary intake was collected from a validated Food Frequency Questionnaire (177 items) and we determined guideline adherence for different food groups. Physical activity was assessed with the Short Questionnaire to ASsess Health enhancing behavior. RESULTS: LDLc data were available in 428 type 2 diabetes mellitus patients. LDLc ≤ 2.5 mmol/l was achieved in 317 patients (76%). In total, 76% of patients used statins, in those with LDLc > 2.5 mmol/l, this was 44%. Adherence to lifestyle guidelines was not different between the LDLc groups and was as follows: body mass index 6%, physical activity 59%, vegetables 7%, fruit 28%, legumes 59%, nuts 14%, dairy 19%, fish 36%, tea 8%, fats 66%, red meat 12%, processed meat 2%, alcohol 71%, sweetened beverages 34%, and sodium 12%. CONCLUSIONS: In type 2 diabetes mellitus patients in secondary health care, the target LDLc is achieved by three quarters of patients. Increasing statin treatment could be a first step to improve LDLc. In addition, there are ample opportunities for lifestyle management through increasing adherence to lifestyle guidelines. Nature Publishing Group UK 2018-04-25 /pmc/articles/PMC5917033/ /pubmed/29695715 http://dx.doi.org/10.1038/s41387-018-0028-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Gant, Christina M.
Binnenmars, S. Heleen
Harmelink, Manon
Soedamah-Muthu, Sabita S.
Bakker, Stephan J. L.
Navis, Gerjan
Laverman, Gozewijn D.
Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title_full Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title_fullStr Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title_full_unstemmed Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title_short Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
title_sort real-life achievement of lipid-lowering treatment targets in the diabetes and lifestyle cohort twente: systemic assessment of pharmacological and nutritional factors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917033/
https://www.ncbi.nlm.nih.gov/pubmed/29695715
http://dx.doi.org/10.1038/s41387-018-0028-y
work_keys_str_mv AT gantchristinam reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT binnenmarssheleen reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT harmelinkmanon reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT soedamahmuthusabitas reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT bakkerstephanjl reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT navisgerjan reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors
AT lavermangozewijnd reallifeachievementoflipidloweringtreatmenttargetsinthediabetesandlifestylecohorttwentesystemicassessmentofpharmacologicalandnutritionalfactors